MicroRNA-125b and cancer

Abstract

Liu Qianqian, He Xiaolan, Tang Lin, Yuan Yixiao, Qiu Shun, Duan Lincan. MicroRNA-125b and cancer[J]. Journal of International Oncology, 2020, 47(2): 90-92.

References20

[1]	Yin H, Sun Y, Wang X , et al. Progress on the relationship between miR-125 family and tumorigenesis[J]. Exp Cell Res, 2015,339(2):252-260. DOI: 10.1016/j.yexcr.2015.09.015.
[2]	Tang XY, Zheng W, Ding M , et al. miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism[J]. Drug Des Devel Ther, 2016,10:571-583. DOI: 10.2147/DDDT.S90530.
[3]	Jin XJ, Chen XJ, Zhang ZF , et al. Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b/STAT3 axis[J]. J Cell Physiol, 2019,234(5):6624-6632. DOI: 10.1002/jcp.27403. doi:10.1002/jcp.27403
[4]	Biamonte F, Battaglia AM, Zolea F , et al. Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis[J]. Cell Death Dis, 2018,9(12):1174. DOI: 10.1038/s41419-018-1216-3.
[5]	Zhao A, Zeng Q, Xie X , et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression[J]. J Genet Genomics, 2012,39(1):29-35. DOI: 10.1016/j.jgg.2011.12.003.
[6]	Ottaviani S, Castellano L . MicroRNAs: novel regulators of the TGF-β pathway in pancreatic ductal adenocarcinoma[J]. Mol Cell Oncol, 2018,5(6):e1499066. DOI: 10.1080/23723556.2018.1499066.
[7]	Zhang J, Na S, Liu C , et al. MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma[J]. Tumour Biol, 2016,37(5):5941-5949. DOI: 10.1007/s13277-015-4409-8.
[8]	Zhang X, Liu Y, Huang WC , et al. miR-125b-1-3p exerts antitumor functions in lung carcinoma cells by targeting S1PR1[J]. Chin Med J (Engl), 2018,131(16):1909-1916. DOI: 10.4103/0366-6999.238135.
[9]	Parayath NN, Parikh A, Amiji MM . Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b[J]. Nano Lett, 2018,18(6):3571-3579. DOI: 10.1021/acs.nanolett.8b00689.
[10]	Wang Y, Zhao M, Liu J , et al. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway[J]. Oncol Rep, 2017,38(3):1715-1723. DOI: 10.3892/or.2017.5808.
[11]	Riquelme I, Tapia O, Leal P , et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway[J]. Cell Oncol (Dordr), 2016,39(1):23-33. DOI: 10.1007/s13402-015-0247-3.
[12]	Tanaka H, Hazama S, Iida M , et al. miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer[J]. Cancer Sci, 2017,108(11):2229-2238. DOI: 10.1111/cas.13390.
[13]	Zhu HR, Huang RZ, Yu XN , et al. Microarray expression profiling of microRNAs reveals potential biomarkers for hepatocellular carcinoma[J]. Tohoku J Exp Med, 2018,245(2):89-98. DOI: 10.1620/tjem.245.89.
[14]	Fan YX, Bian XH, Qian PD , et al. MicroRNA-125b inhibits cell proliferation and induces cell apoptosis in esophageal squamous cell carcinoma by targeting BMF[J]. Oncol Rep, 2018,40(1):61-72. DOI: 10.3892/or.2018.6413.
[15]	Wang Y, Tang P, Chen Y , et al. Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-κB signaling pathway[J]. Biochem Biophys Res Commun, 2017,488(1):60-66. DOI: 10.1016/j.bbrc.2017.05.007.
[16]	Congras A, Caillet N, Torossian N , et al. Doxorubicin-induced loss of DNA topoisomerase Ⅱ and DNMT1- dependent suppression of miR-125b induces chemoresistance in ALK-positive cells[J]. Oncotarget, 2018,9(18):14539-14551. DOI: 10.18632/oncotarget.24465.
[17]	Piatopoulou D, Avgeris M, Marmarinos A , et al. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment[J]. Br J Cancer, 2017,117(6):801-812. DOI: 10.1038/bjc.2017.256.
[18]	邓益民, 罗霭玲, 李广芬 , 等. 下调miR-125b逆转白血病细胞对多柔比星的耐药作用[J]. 中国实验血液学杂志, 2018,26(6):1610-1615. DOI: 10.7534/j.issn.1009-2137.2018.06.005.
[19]	Liu B, Su F, Chen M , et al. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage Ⅱ/Ⅲ breast cancer[J]. Hum Pathol, 2017,64:44-52. DOI: 10.1016/j.humpath.2017.03.016. doi:10.1016/j.humpath.2017.03.016
[20]	Ahram M, Mustafa E, Zaza R , et al. Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells[J]. Cell Biol Int, 2017,41(12):1345-1355. DOI: 10.1002/cbin.10841.

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References20

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.